Cyteir Therapeutics
Publications

Publications

Publications

SELECTIVE CYTEIR AND COLLABORATOR PUBLICATIONS:

SELECTIVE RELATED PUBLICATIONS RELATING TO RAD51:

  • Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: The past or future of cancer treatment? (2016) Pharmacology & Therapetucis 160:65-83
  • Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP. Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51. (2016) J Med Chem 59:4511-25
  • Ward A, Khanna KK, Wiegmans, AP. Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51. (2015) Cancer Treatment Reviews 4: 35-45
  • Scott DE, Coyne AG, Venkitaraman A, Blundell TL, Abell C, Hyvonene M. Small-Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases (2015) Chem Med Chem. 10: 296-303.
  • Mason JM, Logan HL, budke B, Wu M, Pawlowski M, Weichselbaum RR, Kozikowski AP, Bishop DK, Connell PP. The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors. (2014) Cancer Res 74:3546-55.
  • Wiegmans AP, Al-Ejej F, Chee N, Yap P-Y, Gorski JJ, Da Silva L, Boldersoon E, Chenevix-Trench G, Anderson R, Simpson PT, Lakhani SR, Khanna KK. Rad51 supports triple negative breast cancer metastasis. (2014) Oncotarget 5: 3261-3272
  • Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, Breggia A, Hedlund J, Emery I, Cavallo F, Jasin M, Ruter J, Mills KD. Attenuating homologous recombination stimulate an AID-induced antileukemic effect. (2013) J Exp Med 210:1021-33
  • Huhn D, Bolck HA, Sartori AA. Targeting DNA double-strand break signaling and repair: recent advances in cancer therapy. (2013) Eur J Med Sci. Swiss Med Weekly. 143:w13837
  • Renodon-Cornier A, Weigel P, Le Breton M, Fleury F. New Potential Therapeutic Approaches by Targeting Rad51-Dependent Homologous Recombination. (2013) Biochemistry, Genetics, and Molecular Giology. Edited by Clark Chen. ISMB 978-953-51-1114-6.
  • Jayathilaka K, Sheridan SD, Bold TD, Bochenska K, Logan HL, Welchselbaum RR, Bishop DK, Connell PP. A chemical compound that stiumulates the human homologous recombination protein RAD51. (2008) Proc Natl Acad Sci 105:15848-15853

SELECTIVE RELATED PUBLICATIONS RELATING TO AID:

  • Nonaka T, Toda Y, Hiai H, Uemura M, Nakamura M, Yamamoto N, Asato R, Hattori Y, Bessho K, Minato N, Kinoshita K. Involvement of activation-induced cytidine deaminase in skin cancer development. (2016) J Clin Invest.126(4):1367-82
  • Xochelli A, Sutton LA, Agathangelidis A, Stalika E, Karypidou M, Marantidou F, Lopez AN, Papadopoulos G, Supikova J, Groenen P, Boudjogra M, Sundstrom C, Ponzoni M, Francova HS, Anagnostopoulos A, Pospisilova S, Papadaki T, Tzovaras D, Ghia P, Pott C, Davi F, Campo E, Rosenquist R, Hadzidimitriou A, Belessi C, Stamatopoulos K. Molecular evidence for antigen drive in the natural history of mantle cell lymphoma. (2015) Am J Pathol.185(6):1740-8.
  • Lossos IS, Fabregas JC, Koru-Sengul T, Miao F, Goodman D, Serafini AN, Hosein PJ, Stefanovic A, Rosenblatt JD, Hoffman JE. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. (2015) Leuk Lymphoma.56(6):1750-5.
  • Nagata N, Akiyama J, Marusawa H, Shimbo T, Liu Y, Igari T, Nakashima R, Watanabe H, Uemura N, Chiba T. Enhanced expression of activation-induced cytidine deaminase in human gastric mucosa infected by Helicobacter pylori and its decrease following eradication (2014) J Gastroenterol. 49(3):427-35
  • Okura R, Yoshioka H, Yoshioka M, Hiromasa K, Nishio D, Nakamura M. Expression of AID in malignant melanoma with BRAF(V600E) mutation (2014) Exp Dermatol. 23(5):347-8.
  • Gushima M, Hirahashi M, Matsumoto T, Fujita K, Ohuchida K, Oda Y, Yao T, Iida M, Tsuneyoshi M. Expression of activation-induced cytidine deaminase in ulcerative colitis-associated carcinogenesis. (2011) Histopathology 59(3):460-9.
  • Shinmura K, Igarashi H, Goto M, Tao H, Yamada H, Matsuura S, Tajima M, Matsuda T, Yamane A, Funai K, Tanahashi M, Niwa H, Ogawa H, Sugimura H. Aberrant expression and mutation-inducing activity of AID in human lung cancer. (2011) Ann Surg Oncol.18(7):2084-92.
  • Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M. The B cell mutator AID promotes B lymphoid blast crisi and drug resistancce in chronic myeloid leukemia. (2009) Cancer Cell. 8;16(3):232-45.
  • Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. (2007) J Exp Med. 204(5):1157-66.
  • Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, Azuma T, Okazaki IM, Honjo T, Chiba T. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. (2007).Nat Med 13:470-6
  • Pasqualucci L, Guglielmino R, Houldsworth J, Mohr J, Aoufouchi S, Polakiewicz R, Chaganti RS, Dalla-Favera R. Expression of the AID protein in normal and neoplastic B cells. (2004) 104(10):3318-25.